Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

06 July 2012

DOH-FDA ADVISORY
No. 2012-004

SUBJECT: Reported Recall of Hydroxyethylrutoside (VAREMOID FORTE) 200 mg Tablet

Novartis Healthcare Philippines, Inc. has informed this Office of its voluntary recall of its Varemoid Forte 200 mg product SCT Batch 1201 due to presumed contamination with *Pseudomonas aeruginosa* and *Burkholderia cepacia*. Reports have it that the root cause analysis showed that the problem was brought about by the new lot of Narogel used which during release test was not detected but upon the conduct of confirmatory tests appeared to be positive for Pseudomonas aeruginosa and Burkholderia cepacia.

Continuous distribution of the said product present health risk to the consuming sector of the public. Thus, anyone who may have bought the affected products are advise to discontinue using the same and immediately coordinate with the above establiishment.

NICOLAS B. LUTERO, III, Esq., CESO III
Assistant Secretary of Health
Officer-In-Charge – Food and Drug Administration